Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)

Authors :: Tomoyuki Aruga
S. Maeda
Noriyuki Masuda
Masahiro Kitada
K. Aogi
Shoichiro Ohtani
M. Toi
Tomomi Fujisawa
Shuko Morita
Ken-ichi Watanabe
Shinji Ohno
H. Kawaguchi
Takashi Morimoto
Takafumi Sangai
Source :: Annals of Oncology. 29:viii101
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
Second line treatment
business.industry
HER2 negative
Hematology
medicine.disease
law.invention
chemistry.chemical_compound
Breast cancer
chemistry
Randomized controlled trial
law
Internal medicine
medicine
Clinical efficacy
business
Eribulin

Tools